Age-Related Maculopathy Clinical Trial
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01115387 -
GARM II: A Study on the Genetics of Age-related Maculopathy
|
||
| Completed |
NCT00775411 -
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT00511706 -
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
| Terminated |
NCT00474695 -
Study Evaluating Genotypes Using Lucentis
|
N/A | |
| Completed |
NCT00473642 -
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
|
Phase 4 | |
| Completed |
NCT00759044 -
Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function
|
N/A | |
| Completed |
NCT00056823 -
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05752045 -
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
|
N/A | |
| Suspended |
NCT00460967 -
Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis
|
Phase 3 | |
| Completed |
NCT00051129 -
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
| Completed |
NCT01024998 -
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 1 | |
| Completed |
NCT01494805 -
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT01003691 -
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
|
Phase 1 | |
| Terminated |
NCT01577381 -
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT00877032 -
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
|
Phase 1 |